Navigation Links
Obesity and overeating during menopause together promote breast tumor growth and progression
Date:12/7/2012

PHILADELPHIA Obese women might be able to eliminate their increased risk for postmenopausal breast cancer by taking measures during perimenopause to prevent weight gain and to therapeutically control the metabolic effects of their obesity, according to the results of a preclinical study published in Cancer Research, a journal of the American Association for Cancer Research.

"Obese postmenopausal women have increased risk for breast cancer and poorer clinical outcomes compared with postmenopausal women who are lean," said Paul S. MacLean, Ph.D., associate professor of medicine at the University of Colorado Anschutz Health and Wellness Center in Aurora, Colo. "The reasons for this are not fully understood.

"Unfortunately you cannot do the studies needed to address this issue in humans. So, we merged rat models of obesity, breast cancer and menopause to best mimic the events that link premenopausal obesity to an increased rate of postmenopausal breast cancer."

During menopause, women often gain weight because they consume more food than their body needs. In a previous study, MacLean and colleagues used their rat model to show that weight gain following surgical ovariectomy, which models menopause, helped promote breast tumor development in obese rats.

In this study, they confirmed that obesity and overfeeding after surgical ovariectomy together drove aggressive tumor growth and progression.

One reason was that obese rats were unable to appropriately handle the excess sources of energy, in the form of glucose and dietary fat, which accumulated as a result of overfeeding after surgical ovariectomy. Lean rats stored the excess glucose and dietary fat from overfeeding in liver, fat, muscle and healthy breast tissue, a normal metabolic response to overfeeding. In contrast, the healthy tissues in obese rats failed to increase uptake of glucose and dietary fat, but the breast tumors dramatically increased uptake of glucose.

A second reason for the enhanced tumor growth and progression in obese rats compared with lean rats was that tumors from the two groups of animals had different molecular profiles. Tumors from obese rats had higher levels of expression of the progesterone receptor (PR), which was related to higher expression of genes involved in energy use and proliferation.

A similar pattern of increased expression of genes involved in energy use and cell growth was seen in human PR-positive breast tumors from postmenopausal women. According to MacLean, a final piece of evidence indicating that obesity and overfeeding during the menopausal transition converge to promote tumor growth and progression was that the antidiabetic drug metformin reduced tumor burden in obese rats after surgical ovariectomy.

"If our findings in rats translate to humans, it means that the perimenopausal period is a critical window of time for determining breast cancer risk later in life," said MacLean. "This, in turn, means that an obese woman's risk for postmenopausal breast cancer and poor clinical outcome could be reduced by perimenopausal lifestyle modifications, such as restricting food consumption and increasing exercise, and/or perimenopausal use of drugs, such as metformin, to improve metabolic control."

MacLean and colleagues are now testing this hypothesis in the rat model.


'/>"/>
Contact: Jeremy Moore
jeremy.moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. LSUHSC research finding keys to future obesity & related diseases
2. Mouse Study Offers Clues to Obesity-Diabetes Link
3. Use Social Media to Fight Childhood Obesity, Heart Experts Say
4. Scientists discover mechanism that could reduce obesity
5. Obese but happy gene challenges the common perception of link between depression and obesity
6. Study Supports Link Between Obesity, Cavities in Homeless Kids
7. Research strengthens link between obesity and dental health in homeless children
8. Childhood obesity more likely to affect children in poorer neighborhoods
9. Obesity epidemic threatens health of all social groups equally
10. U.S. Med Students May Be Undereducated on Obesity
11. Study Ties Obesity-Related Gene to Weaker Memory
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... VA (PRWEB) , ... June 23, 2017 , ... ... of what is needed and will ultimately do significant harm to people with ... to everyone. , "While it leaves in place the Affordable Care Act ...
(Date:6/23/2017)... ... June 24, 2017 , ... Studies show evidence that carotenoids and ... of visual loss in these patients. , But how often do ophthalmologists and optometrists ... to patients at risk of or with early symptoms of AMD? A study ...
(Date:6/23/2017)... ... 2017 , ... Military Connection friend and veteran advocate Micaela Bensko ... Atlantic lounge. , Bensko is no stranger to the plight of the disabled. ... life to supporting our wounded veterans. A world-class photographer, her riveting photos “The Wounds ...
(Date:6/23/2017)... ... 2017 , ... The Aesthetic Channel has recently highlighted Dr. Ben Talei’s unique ... a proprietary technique that he calls the AuraLyft Facelift. The AuraLyft does ... patients can expect to look refreshed, rejuvenated, and revitalized. , Dr. Talei’s unique ...
(Date:6/23/2017)... ... June 23, 2017 , ... 21 Middle East and South Asia ... 21 leaders from government, business and civil society in 11 countries across the Middle ... fall, engaging in a transformative exchange of knowledge and ideas with the leading minds ...
Breaking Medicine News(10 mins):
(Date:6/8/2017)... 2017  StatLab Medical Products ("StatLab" or ... of diagnostic supplies for the anatomic pathology ... Company LP ("Cressey & Company"), a healthcare-focused ... investment in the Company. Cressey & Company ... selling shareholder, Prairie Capital, L.P., with certain ...
(Date:6/7/2017)... 2017  Diplomat Specialty Infusion Group, a brand of Diplomat Pharmacy, ... Iowa location. The ... features an ISO 7 cleanroom—the standard needed to compound intravenous (IV) ... level of pollutants. "Our new ... better serve our Iowa patients," said ...
(Date:6/3/2017)... June 3, 2017  Eli Lilly and Company ... results from the Phase 3 MONARCH 2 study ... 6 inhibitor, in combination with fulvestrant, significantly improved ... alone in women with hormone-receptor-positive (HR+), human epidermal ... who have relapsed or progressed after endocrine therapy ...
Breaking Medicine Technology: